NASDAQ: BDSXBiodesix Inc Stock
$0.43+0.00 (+0%)
Updated Sep 2, 2025
BDSX Price
$0.43
Fair Value Price
N/A
Market Cap
$63.61M
52 Week Low
$0.17
52 Week High
$1.91
P/E
-1.55x
P/B
5.75x
P/S
1.23x
PEG
N/A
Dividend Yield
N/A
Revenue
$74.46M
Earnings
-$40.42M
Gross Margin
78.4%
Operating Margin
-44.32%
Profit Margin
-54.3%
Debt to Equity
6.8
Operating Cash Flow
-$42M
Beta
0.91
Next Earnings
Oct 30, 2025
Ex-Dividend
N/A
Next Dividend
N/A
BDSX Overview
Biodesix, Inc. operates as a data-driven diagnostic solutions provider. Biodesix offers blood-based tests to assess the risk of lung cancer, identify the appropriate treatment pathway, and help physicians to reclassify the risk of malignancy in patients with suspicious lung nodules. Biodesix was incorporated in 2005 and is headquartered in Boulder, CO.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine BDSX's potential to beat the market
- BDSX doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Diagnostic & Research
Industry Rating
C
BDSX
RankedUnranked of 42
RankedUnranked of 42
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $15.50 | A | |
| $16.16 | A | |
| $639.45 | B |
Be the first to know about important BDSX news, forecast changes, insider trades & much more!
BDSX News
Overview
Due Diligence Score
–
Industry Average (26)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how BDSX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
BDSX is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
BDSX is poor value based on its book value relative to its share price (5.75x), compared to the US Diagnostics & Research industry average (3.84x)
P/B vs Industry Valuation
BDSX is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more BDSX due diligence checks available for Premium users.
Valuation
BDSX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.55x
Industry
22.02x
Market
34.73x
BDSX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
5.75x
Industry
3.84x
BDSX is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
BDSX's financial health
Profit margin
Revenue
$18.0M
Net Income
-$11.1M
Profit Margin
-61.8%
BDSX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
BDSX's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$86.2M
Liabilities
$75.2M
Debt to equity
6.8
BDSX's short-term assets ($29.62M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BDSX's long-term liabilities ($61.87M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BDSX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$8.6M
Investing
-$137.0k
Financing
$97.0k
BDSX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
BDSX vs Diagnostic & Research Stocks
Biodesix Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.